I prefer diversified high risk, high reward investing. Biotechs are a current favorite. In 2014, up 34.5% (117 times the S&P), and Stocktwits is a big reason. Happy with the result, but still cautious.
I'm Steven Chase, battle-tested trader/investor since 1996. Managing Partner Rosemarkie Capital Partners, managed a Barron's recognized small cap newsletter. By day, a Director of Software Engineering at a firm in Northern VA.